

This Week's AIM Highlights

Harland & Wolff

Harland & Wolff Group Holdings said they were disappointed that the Isles of Scilly Steamship Company Limited (ISSCL) has unequivocally rejected a preliminary proposal regarding a possible cash offer for the acquisition of the entire issued share capital of ISSCL. Harland & Wolff believe there is a compelling strategic and financial rationale for bringing the Penzance to Isles of Scilly ferry service under the Harland & Wolff umbrella.

RUA Life Sciences

On Monday, RUA Life Sciences released a strategy update noting it had received interest for one of its core products that could be worth £1.5m. The company also alluded to other customer interest that could be worth £0.5m. On Friday, the company issued a trading statement revealing revenue in their half-year fell to £794k, a drop of 28%.

Helium One

Helium One have ceased operations at the Tai-3 well in Tanzania after the recent drill campaign was prevented to reaching its target due to structural issues. Helium One will now target a drilling campaign at a new Itumbula location after repairs on their rig are completed.

Poolbeg Pharma

Poolbeg Pharma announced the Japanese Patent Office has decided to grant the Company's Immunomodulator II patent application. This newly granted Japanese patent builds on the Immunomodulator I patent granted in September, and bolsters Poolbeg's robust portfolio of patents securing the use of POLB 001 and p38 MAP kinase inhibitors to combat severe influenza and hypercytokinemia globally.

Oriole Resources

Oriole Resources, an West Africa focused exploration company, has signed non-binding Heads of Terms (HoT) with Ghana-based mining contractor BCM International across two gold projects in Cameroon - the 92.2% owned Bibemi gold project in northern Cameroon, where BCM will earn-in to fast-track development, and the 90% owned Mbe gold license in central Cameroon, where BCM will earn-in to accelerate exploration. Conditional Earn-In Agreements for both projects are expected to be executed before year-end following these HoT signatures with the well-respected contractor.

This is a marketing communication and contains general information and should not be relied upon to enter any financial transaction. Kemeny Capital is exclusively aimed at UK resident persons who are required to self-certify as either a Sophisticated Investor or a High Net Worth Individual.

Kemeny Capital

Kemeny Capital Ltd is Authorised and Regulated by the Financial Conduct Authority, FCA Register Number 941978. Kemeny Capital, 71-75 Shelton Street, London, Registered in England, Company Number 12871856.

www.kemenycapital.com

Harland & Wolff

As of 24th November

Ticker	HARL
Share Price (p)	12
Market Cap (£m)	20.8

RUA Life Sciences

As of 24th November

Ticker	RUA
Share Price (p)	28
Market Cap (£m)	7

Helium One

As of 24th November

Ticker	HE1
Share Price (p)	3
Market Cap (£m)	29.1

Poolbeg Pharma

As of 24th November

Ticker	POLB
Share Price (p)	9.85
Market Cap (£m)	48.5

Oriole Resources

As of 24th November

Ticker	ORR
Share Price (p)	0.16
Market Cap (£m)	6.3

Important Information

This report has been prepared and distributed by Kemeny Capital and has been compiled for informational purposes only. The information contained is collated from a wide range of publicly available sources, however, Kemeny Capital does not take any responsibility for the accuracy or completeness of the information nor are they responsible for any errors, omissions, or loss resulting from use of such information.

This is a marketing communication and contains general information and should not be relied upon to enter any financial transaction. This guide does not constitute a direct offer, inducement or invitation to invest, subscribe or purchase any securities. This guide is not legal, tax or financial advice and nor should it be taken as such.

Kemeny Capital Ltd is Authorised and Regulated by the Financial Conduct Authority, FCA Register Number 941978. Registered in England, Company Number 12871856

This publication has been issued and approved by Kemeny Capital Ltd.

Risk Warning

Kemeny Capital is exclusively aimed at UK resident persons who are required to self-certify as either a Sophisticated Investor or a High Net Worth Individual.

The value of investments may go up as well as down and there is no guarantee of any investment return. Investments in private companies carry significant risks including loss of capital, illiquidity, and no guarantee of regular income from the investment. You should understand the risks involved and be capable of making investment decisions based upon your personal circumstances. Past Performance is not an indicator of future performance.

Tax relief depends on an individual's circumstances and may change in the future. In addition, the availability of tax relief depends on the company invested in maintaining its qualifying status.